|
JP3415145B2
(ja)
*
|
1991-03-05 |
2003-06-09 |
ザ ウエルカム ファウンデーション リミテッド |
弱毒化細菌における組換えタンパク質の発現
|
|
US5961974A
(en)
*
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
|
KR100283541B1
(ko)
|
1991-10-25 |
2001-03-02 |
크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 |
신규 사이토킨
|
|
US5962406A
(en)
*
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
US5716805A
(en)
*
|
1991-10-25 |
1998-02-10 |
Immunex Corporation |
Methods of preparing soluble, oligomeric proteins
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5981724A
(en)
*
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
US5540926A
(en)
*
|
1992-09-04 |
1996-07-30 |
Bristol-Myers Squibb Company |
Soluble and its use in B cell stimulation
|
|
EP0659086B1
(en)
*
|
1992-09-04 |
1998-11-11 |
The University of Saskatchewan |
Novel bacterial vaccines using vaccine strains of pathogenic bacteria
|
|
US5565321A
(en)
*
|
1993-01-22 |
1996-10-15 |
Immunex Corporation |
Detection of mutations in a CD40 ligand gene
|
|
AU1059095A
(en)
|
1993-11-24 |
1995-06-13 |
Australian National University, The |
Treatment of viral disease with cd40l peptide
|
|
ES2251719T3
(es)
*
|
1994-04-28 |
2006-05-01 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Metodos para la proliferacion y diferenciacion de celulas b y su empleo.
|
|
EP0812206B1
(en)
|
1995-03-01 |
2002-07-10 |
Immunex Corporation |
Cd40 binding protein for stimulating an immune response
|
|
ES2214541T3
(es)
|
1995-06-07 |
2004-09-16 |
Immunex Corporation |
Muteina de cd40l.
|
|
US6713279B1
(en)
*
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6479258B1
(en)
*
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6306387B1
(en)
*
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
*
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
AU2004199A
(en)
|
1997-12-19 |
1999-07-12 |
Immunex Corporation |
Method for reducing susceptibility to hiv infection
|
|
GB9806449D0
(en)
*
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
*
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
DK1108034T3
(da)
*
|
1998-09-04 |
2008-11-10 |
Emergent Product Dev Uk Ltd |
Svækkede salmonella SPI2-mutanter som antigenbærere
|
|
US7300774B1
(en)
*
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
AU3966200A
(en)
|
1999-04-16 |
2000-11-02 |
F. Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
US7803765B2
(en)
*
|
1999-05-05 |
2010-09-28 |
Phylogica Limited |
Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
|
|
AU1084901A
(en)
*
|
1999-10-14 |
2001-04-23 |
Martha S. Hayden-Ledbetter |
Dna vaccines encoding antigen linked to a domain that binds cd40
|
|
ES2222152T3
(es)
*
|
1999-12-28 |
2005-02-01 |
Akzo Nobel N.V. |
Vacuna con las salmonellas que no inducen anticuerpos que reaccionan con la flagelina o los flagelos.
|
|
US7371392B2
(en)
*
|
2000-02-02 |
2008-05-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cd40 ligand adjuvant for respiratory syncytial virus
|
|
DE60112413T2
(de)
*
|
2000-03-17 |
2006-06-01 |
Pharmacia & Upjohn Co. Llc, Kalamazoo |
Ssa inaktivierte salmonella impfstoffe
|
|
GB0015426D0
(en)
*
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
US20030165538A1
(en)
|
2000-06-26 |
2003-09-04 |
Maxygen Incorporated |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
WO2002036769A2
(en)
|
2000-10-31 |
2002-05-10 |
F. Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
US6855493B2
(en)
*
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
CA2447593C
(en)
|
2001-05-15 |
2014-07-08 |
Ortho-Mcneil Pharmaceutical, Inc. |
Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
|
|
CN100348608C
(zh)
*
|
2001-07-06 |
2007-11-14 |
Abic特瓦生物实验室有限公司 |
编码重组的来源于巨型艾美球虫子孢子/裂殖子的250kDa抗原的核酸,和它们的应用
|
|
ZA200400479B
(en)
|
2001-07-06 |
2006-05-31 |
Abic Biolog Lab Teva |
Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
US7378089B2
(en)
|
2001-10-02 |
2008-05-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Gene therapy for the prevention of autoimmune disease
|
|
US7238499B2
(en)
*
|
2001-12-21 |
2007-07-03 |
Immunex Corporation |
Trimeric macrophage scavenger receptor fusion proteins and encoding nucleic acids
|
|
WO2003067991A1
(en)
*
|
2002-02-13 |
2003-08-21 |
Immunology Laboratories, Inc. |
Compositions and methods for treatment of microbial infections
|
|
US6923958B2
(en)
*
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
EP1499191B1
(en)
*
|
2002-04-15 |
2012-05-09 |
Washington University in St. Louis |
Regulated attenuation of live vaccines to enhance cross protective immunogenicity
|
|
US7495090B2
(en)
*
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
US20060014248A1
(en)
*
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US20050181994A1
(en)
*
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US7754209B2
(en)
*
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
WO2005035570A2
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc. |
Variants of cd40l protein
|
|
EP1720905A2
(en)
|
2003-12-11 |
2006-11-15 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
US8828957B2
(en)
*
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
EP1809737B9
(en)
*
|
2004-10-07 |
2011-10-05 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
US8513008B2
(en)
*
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
US20060286074A1
(en)
*
|
2005-05-31 |
2006-12-21 |
Yucheng Tang |
Methods for immunotherapy of cancer
|
|
BRPI0616978A2
(pt)
*
|
2005-10-07 |
2011-07-05 |
Proyecto Biomedicina Cima Sl |
combinação imuno-estimulante para a profilaxia e tratamento de hepatite c, sua utilização, composição farmacêutica que a contém, kit para sua administração, método para produzir uma resposta imune e vacina contra o vìrus da hepatite c
|
|
AU2006311752A1
(en)
*
|
2005-11-07 |
2007-05-18 |
Sidney Kimmel Cancer Center |
CD40 ligand fusion protein vaccine
|
|
DE102005054643B3
(de)
|
2005-11-10 |
2007-02-15 |
Assa Abloy Sicherheitstechnik Gmbh |
Schließzylinder
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
CU23576A1
(es)
*
|
2006-02-28 |
2010-09-30 |
Ct Ingenieria Genetica Biotech |
Antígenos vacunales quiméricos contra el virus de la influenza aviar
|
|
WO2007103048A2
(en)
*
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
WO2007106073A2
(en)
*
|
2006-03-02 |
2007-09-20 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
FR2898905B1
(fr)
*
|
2006-03-24 |
2008-05-09 |
Rhodia Recherches & Tech |
Composition polyisocyanate a proprietes anti-chocs ameliorees
|
|
WO2008027394A2
(en)
*
|
2006-08-28 |
2008-03-06 |
The Wistar Institute Of Anatomy And Biology |
Constructs for enhancing immune responses
|
|
KR101460551B1
(ko)
|
2006-09-18 |
2014-11-18 |
더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 |
면역 반응을 향상시키는 조성물 및 방법
|
|
EP2139913A4
(en)
*
|
2007-03-08 |
2011-09-21 |
Mayo Foundation |
INTRODUCTION OF IMMUNE-MEDIUM TUMOR CELL DEOD
|
|
CN101024076B
(zh)
*
|
2007-03-29 |
2010-08-18 |
中国农业大学 |
球虫的新用途
|
|
EP3321277B1
(en)
*
|
2007-07-10 |
2019-09-18 |
Apogenix AG |
Tnf superfamily collectin fusion proteins
|
|
AU2008318615A1
(en)
|
2007-10-30 |
2009-05-07 |
Texas A&M University System |
Compositions and methods of enhancing immune responses to flagellated bacterium
|
|
CA2704422C
(en)
*
|
2007-11-01 |
2019-09-24 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses to eimeria
|
|
HUE025236T2
(en)
*
|
2008-07-21 |
2016-03-29 |
Apogenix Gmbh |
TNFSF single chain molecules
|
|
US8316310B2
(en)
|
2008-08-05 |
2012-11-20 |
International Business Machines Corporation |
System and method for human identification proof for use in virtual environments
|
|
EP2184229B1
(en)
*
|
2008-11-11 |
2012-10-17 |
AGUSTAWESTLAND S.p.A. |
Helicopter rotor
|
|
US20100150958A1
(en)
*
|
2008-12-15 |
2010-06-17 |
Vectogen Pty Ltd. |
Methods and Compositions for Use of a Coccidiosis Vaccine
|
|
DK2525817T3
(en)
*
|
2010-01-21 |
2017-10-02 |
Univ Arkansas |
Vaccine vectors and methods for enhancing immune responses
|
|
HRP20201513T1
(hr)
*
|
2011-10-11 |
2020-12-11 |
Viela Bio, Inc. |
Cd40l-specifični tn3-izvedeni skeleti i postupci njihove uporabe
|
|
WO2014043215A1
(en)
*
|
2012-09-11 |
2014-03-20 |
The Texas A&M University System |
Bi-specifc diabodies for masking and targeting vaccines
|
|
JP6284537B2
(ja)
*
|
2012-10-29 |
2018-02-28 |
ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー |
新規粘膜アジュバントおよびデリバリーシステム
|
|
EA030929B1
(ru)
*
|
2013-02-14 |
2018-10-31 |
Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас |
КОМПОЗИЦИИ И СПОСОБЫ УСИЛЕНИЯ ИММУННЫХ ОТВЕТОВ НА Eimeria ИЛИ ОГРАНИЧЕНИЯ ИНФЕКЦИИ Eimeria
|
|
HK1219045A1
(zh)
*
|
2013-03-15 |
2017-03-24 |
The Board Of Trustees Of The University Of Arkansas |
增强对肠道病原体免疫应答的组合物和方法
|
|
JP2017523136A
(ja)
*
|
2014-06-05 |
2017-08-17 |
ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー |
抗体誘導ワクチン及び迅速な成熟免疫応答の発生のための使用方法
|
|
US20160090603A1
(en)
*
|
2014-09-30 |
2016-03-31 |
Sandia Corporation |
Delivery platforms for the domestication of algae and plants
|
|
CN109715207B
(zh)
*
|
2016-03-29 |
2023-03-31 |
南加利福尼亚大学 |
靶向癌症的嵌合抗原受体
|
|
KR20220028143A
(ko)
*
|
2016-05-27 |
2022-03-08 |
애브비 바이오테라퓨틱스 인크. |
항-cd40 항체 및 이의 용도
|
|
CN109803977B
(zh)
*
|
2016-08-17 |
2023-03-17 |
菲克特生物科学股份有限公司 |
核酸产品及其施用方法
|